Lack of bromocriptine-induced reduction of predicted height in tall adolescents

Détails

ID Serval
serval:BIB_0182EFA3C26C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Lack of bromocriptine-induced reduction of predicted height in tall adolescents
Périodique
Journal of Clinical Endocrinology and Metabolism
Auteur⸱e⸱s
Schoenle  E. J., Theintz  G., Torresani  T., Prader  A., Illig  R., Sizonenko  P. C.
ISSN
0021-972X (Print)
Statut éditorial
Publié
Date de publication
08/1987
Volume
65
Numéro
2
Pages
355-8
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Aug
Résumé
Fifteen girls and five boys with excessive predicted adult height (chronological age, 10.1-14.6 yr; bone age, 11.0-14.0 yr) were treated with bromocriptine (two doses; 2.5 mg/day) to reduce their final height. After a mean treatment period of 1.14 yr (range, 0.6-1.75 yr) we did not find a reduction of predicted adult height [difference, -0.5 +/- 3.5 (+/- SD) cm according to Bayley and Pinneau's tables (P = NS) and +0.2 +/- 2.5 (+/- SD) cm according to the method of Tanner (P = NS)]. Mean peak plasma GH concentrations after TRH administration before and during bromocriptine were 51.5 +/- 49.4 and 58.5 +/- 50.7 mU/L, respectively. The wide range of the GH values may be explained by physiological variation in this age group. After ingestion of 2.5 mg bromocriptine a significant increase in plasma GH occurred within 3 h in six adolescents tested. Our results do not support the concept that bromocriptine may reduce predicted adult height in tall adolescents by decreased GH secretion or acceleration of skeletal maturation.
Mots-clé
Adolescent Age Determination by Skeleton Body Height/*drug effects Bromocriptine/*therapeutic use Child Female Growth Hormone/blood Humans Male Thyrotropin-Releasing Hormone/diagnostic use
Pubmed
Web of science
Création de la notice
25/01/2008 10:31
Dernière modification de la notice
20/08/2019 12:23
Données d'usage